In vivo evaluation of ixabepilone (BMS247550), a novel epothilone B derivative, against pediatric cancer models.
about
Initial testing of the replication competent Seneca Valley virus (NTX-010) by the pediatric preclinical testing programStabilizing versus destabilizing the microtubules: a double-edge sword for an effective cancer treatment option?Children's Oncology Group's 2013 blueprint for research: renal tumorsCharacterization of a WiT49 cell line derived orthotopic model of Wilms tumor.Initial testing of VNP40101M (Cloretazine) by the pediatric preclinical testing program.Initial testing of the aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP).Initial testing of topotecan by the pediatric preclinical testing program.Initial testing (stage 1) of the Akt inhibitor GSK690693 by the pediatric preclinical testing program.Initial testing of a monoclonal antibody (IMC-A12) against IGF-1R by the Pediatric Preclinical Testing Program.Stage 2 combination testing of rapamycin with cytotoxic agents by the Pediatric Preclinical Testing ProgramInitial testing (stage 1) of AZD6244 (ARRY-142886) by the Pediatric Preclinical Testing Program.Novel microtubule-targeting agents - the epothilones.Phase II trial of ixabepilone administered daily for five days in children and young adults with refractory solid tumors: a report from the children's oncology groupA HPLC method for the quantitative determination of N-(2-hydroxy-5-nitrophenylcarbamothioyl)-3,5-dimethylbenzamide in biological samples.Initial testing of the hypoxia-activated prodrug PR-104 by the pediatric preclinical testing program.Testing of the topoisomerase 1 inhibitor Genz-644282 by the pediatric preclinical testing program.The microtubule stabilizer patupilone (epothilone B) is a potent radiosensitizer in medulloblastoma cells.Initial testing of the CENP-E inhibitor GSK923295A by the pediatric preclinical testing program.Combination testing (Stage 2) of the Anti-IGF-1 receptor antibody IMC-A12 with rapamycin by the pediatric preclinical testing program.Efficacy and pharmacokinetic/pharmacodynamic evaluation of the Aurora kinase A inhibitor MLN8237 against preclinical models of pediatric cancer.Combination testing of cediranib (AZD2171) against childhood cancer models by the pediatric preclinical testing program.Initial testing of lenalidomide by the pediatric preclinical testing programInitial testing (stage 1) of the cyclin dependent kinase inhibitor SCH 727965 (dinaciclib) by the pediatric preclinical testing program.Initial testing (stage 1) of the tubulin binding agent nanoparticle albumin-bound (nab) paclitaxel (Abraxane(®)) by the Pediatric Preclinical Testing Program (PPTP).Identification of Synergistic, Clinically Achievable, Combination Therapies for OsteosarcomaInitial testing of the MDM2 inhibitor RG7112 by the Pediatric Preclinical Testing ProgramInitial testing (stage 1) of the anti-microtubule agents cabazitaxel and docetaxel, by the pediatric preclinical testing program.New drugs for the treatment of metastatic or refractory soft tissue sarcomas in children.Monitoring therapy with MEK inhibitor U0126 in a novel Wilms tumor model in Wt1 knockout Igf2 transgenic mice using 18F-FDG PET with dual-contrast enhanced CT and MRI: early metabolic response without inhibition of tumor growth.Treatment of neuroblastoma and rhabdomyosarcoma using RGD-modified liposomal formulations of patupilone (EPO906).Phase I trial and pharmacokinetic study of ixabepilone administered daily for 5 days in children and adolescents with refractory solid tumorsEpothilones: a novel class of microtubule-stabilizing drugs for the treatment of cancer.A phase I/II trial and pharmacokinetic study of ixabepilone in adult patients with recurrent high-grade gliomas.Sagopilone crosses the blood-brain barrier in vivo to inhibit brain tumor growth and metastasesInitial testing of the investigational NEDD8-activating enzyme inhibitor MLN4924 by the pediatric preclinical testing program.Initial testing (stage 1) of lapatinib by the pediatric preclinical testing program.Initial testing (stage 1) of the kinesin spindle protein inhibitor ispinesib by the pediatric preclinical testing program.Initial testing of aplidin by the pediatric pre-clinical testing program.Initial testing (stage 1) of mapatumumab (HGS-ETR1) by the pediatric preclinical testing program.Microtubule-targeting agents in oncology and therapeutic potential in hepatocellular carcinoma.
P2860
Q24627862-FA1A91B1-A453-474F-933A-5661DDF21997Q26781365-2638BA0D-E755-4879-9A4A-5DA1DEABD226Q27000449-257BD110-CDC0-474D-A938-DADFC588E37FQ33709909-C3147522-CAA0-4B16-95AE-2E4506CE4BFFQ33718154-3DF0208F-0526-42CF-874C-9AA149FA6264Q33867046-352CD9FF-8A8B-4C2D-96ED-CB4324433FB4Q34073784-809D175F-ECC2-4F5C-9D95-E853EC16328AQ34249719-0F09A92F-64B2-44C0-8FA2-C11930EA7122Q34414710-6F0CB944-C399-47FC-9F8B-B55330FCB5D4Q34414736-6F387FAE-7B2C-42F0-8590-C580FE6143D0Q34415484-9260A060-6931-4654-8E51-48B76C288181Q34611212-8DC5D0BA-9126-4132-8D1C-8A7369044E91Q34915389-027261F5-AC62-40E8-8BBF-57299CA0EA42Q34988900-AFC320E7-C497-4D09-945A-DB5A3C1A8CA3Q35005290-15EAA08B-E6FB-462D-84E0-4F0DF5E2EFDAQ35161137-1E8577C5-19A8-496C-99EE-EEA8898B004BQ35170345-64481A03-6038-4A2E-BAD4-6EA03826DBC8Q35186275-AFD69C95-0AAE-4E35-B0FF-F2C19C25C0E6Q35194644-342FCAD6-75DE-43A4-9B59-FCC3C69F8E1EQ35549470-939195EF-6A68-42DE-9E8C-A06EAE832F20Q35659433-332EEE18-93BC-48EE-8F2D-44BC34E9B2BEQ35861457-C92E2FD2-25EA-4C09-82DC-B13A368F7D73Q35951806-CB9F2CCE-79DA-4489-A9E4-A8E5B868E753Q36040758-968507BA-0205-43A6-8087-FA77947A4530Q36316518-974F5E67-480D-4DBE-9550-884474E41B13Q36392660-734F805F-F923-437A-A9A5-D885A8D67D3EQ36592309-D545EEFF-EFB9-432C-B8DF-B8D0477E83D5Q36616537-26C6042B-E798-4D4A-8FBA-6BC075724BEAQ36665931-12252FDD-E077-4540-AE77-24095B6EDF7BQ36957962-526B2BCC-2B65-408D-83C8-FBDA56B07E46Q37104791-D6D2380E-3C9A-4595-BDCE-97030A495A52Q37236419-CA5DDC12-7B34-4111-878B-7F643561D8CFQ37262792-FDBD9C53-E1D8-4A6F-8486-BD36DAA9795BQ37284300-DB326587-4525-4B34-A97F-D2EB9C02AF53Q37295143-55051552-91BC-445E-BEBA-ADDC1D088F7DQ37316174-A6BC6919-5636-474D-9BFF-AC5209FBC522Q37392282-13DA3A28-BA97-4C4E-865A-AF06EED92716Q37421824-8AB6156E-E5B4-4984-86D4-3FF4C3E57E30Q37480185-B996B3E4-8EC7-4114-B80B-B61BC4EEE298Q37722656-CD888072-F303-41A8-BE41-C31368C9670E
P2860
In vivo evaluation of ixabepilone (BMS247550), a novel epothilone B derivative, against pediatric cancer models.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
In vivo evaluation of ixabepil ...... ainst pediatric cancer models.
@en
type
label
In vivo evaluation of ixabepil ...... ainst pediatric cancer models.
@en
prefLabel
In vivo evaluation of ixabepil ...... ainst pediatric cancer models.
@en
P2093
P1476
In vivo evaluation of ixabepil ...... ainst pediatric cancer models.
@en
P2093
Catherine A Billups
Chandra Tucker
Edward Favours
Francis Y F Lee
Jennifer K Peterson
Jeremy Creech
Pamela J Cheshire
Peter J Houghton
Richard Smykla
P304
P356
10.1158/1078-0432.CCR-05-0740
P407
P433
P577
2005-10-01T00:00:00Z